Biopharmaceutical News and Research

RSS

Penn engineers cook up a new way for safer, more effective mRNA therapies

Penn Engineers have cooked up a new way to improve mRNA delivery, developing an optimal "recipe" for ionizable lipids - key ingredients in lipid nanoparticles (LNPs), the molecules behind the COVID-19 vaccines and other innovative therapies.

22 Nov 2024

10x Genomics and Beckman Coulter Life Sciences Launch New Solution to Automate Single Cell Assay Workflows

10x Genomics and Beckman Coulter Life Sciences, announce the commercial availability of a new solution to automate single cell gene expression workflows.

From Beckman Coulter Life Sciences - Flow Cytometry 19 Nov 2024

UCL scientists receive £78 million funding boost to develop treatment for motor neurone disease

A funding boost of more than £78 million will help UCL scientists working to develop a potential treatment for motor neurone disease, for which there is currently no cure and which affects 5,000 people each year in the UK.

14 Nov 2024

UAB researchers reverse liver disease in mice with gene therapy

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than 40 million people.

13 Nov 2024

Utilizing process Raman in optimizing cultivated meat production

Learn about the usage of process raman spectroscopy in the optimization of bioreactor monitoring and then improvement of cultivated meat production.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 13 Nov 2024

Adipo Therapeutics shares results of studies on potential obesity treatment

Adipo Therapeutics LLC, a late-stage, preclinical biopharmaceutical company developing a potential treatment for obesity and related metabolic disorders, presented data from two studies at the annual meeting of The Obesity Society in San Antonio.

7 Nov 2024

Lupus Research Alliance announces 33 studies to be presented at ACR Convergence 2024

The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that a total of 33 studies, funded by the organization or supported by its clinical research affiliate Lupus Therapeutics, will be presented at ACR Convergence 2024.

5 Nov 2024

INTEGRA Biosciences’ pipettes help progress small molecule inhibitors from discovery to clinical trials

RAPT Therapeutics in San Francisco, USA, relies on INTEGRA Biosciences’ pipettes to seamlessly accelerate the development of its candidate small molecule inhibitors for the treatment of inflammatory diseases and cancers.

From INTEGRA Biosciences 22 Oct 2024

New grant aims to transform treatment for liver cancer

Currently, there are a few available treatment options for liver cancer, including a combination of immunotherapies and a class of drugs known as tyrosine kinase inhibitors (TKIs), but their long-term effects are limited.

17 Oct 2024

AI's potential to improve healthcare access could be offset by exploitation

As tools powered by artificial intelligence increasingly make their way into health care, the latest research from UC Santa Cruz Politics Department doctoral candidate Lucia Vitale takes stock of the current landscape of promises and anxieties.

9 Oct 2024

Owkin partners with AstraZeneca to enhance gBRCA testing for breast cancer

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

4 Oct 2024

Beckman Coulter Life Sciences Names Joe Fox President

...

From Beckman Coulter Life Sciences - Flow Cytometry 1 Oct 2024

Early specificity testing crucial for antibody drug safety

Integral Molecular, a leader in antibody discovery and characterization, has published new research in the journal mAbs, revealing that as many as one-third of antibody-based drugs exhibit nonspecific binding to unintended targets.

18 Sep 2024

Ohio State's novel DHODH inhibitor enters first human trials

A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the patient's bedside as part of a clinical trial.

17 Sep 2024

Sino Biological and BioGeometry Deepen Strategic Cooperation to Empower Protein R&D with Generative AI

Sino Biological, a leading recombinant protein production company, is pleased to announce an expansion of its strategic partnership with BioGeometry, a pioneer in digital biology.

From Sino Biological Inc. 12 Sep 2024

SCIEX summit - Highlighting scientific breakthroughs in mass spectrometry that really count

Join scientists and researchers from around the globe to discuss the importance of LC-MS in fields like food and environmental testing, pharmaceutical and biopharmaceutical discovery and development and biomedical and omics research.

From SCIEX 9 Sep 2024

Study reveals key bacteria for developing personalized probiotics for newborns

Newborn babies have one of three pioneer bacteria in their gut shortly after birth, one of which could be used to develop new personalized infant therapeutic probiotics, researchers show.

6 Sep 2024

Akebia Therapeutics to present at upcoming investor conferences

Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 4-6, 2024 in Boston and H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024 in New York.

From Akebia Therapeutics 4 Sep 2024

Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of final data from the RESTORE open-label/switch study, demonstrating that people with narcolepsy prefer once-at-bedtime LUMRYZ versus a twice-nightly immediate-release oxybate treatment option.

From Avadel Pharmaceuticals 4 Sep 2024

Triple-pill combination GMRx2 outperforms standard care in lowering blood pressure

New research shows that a treatment plan based on novel combination of low doses of three anti-hypertensive drugs in a single pill - known as GMRx2 - was superior to a high-quality standard care treatment plan at lowering blood pressure in patients with uncontrolled hypertension.

1 Sep 2024